Abstract
Depressive disorders are common sequelae of cancer and its treatment. Fortunately, most of them are transient and respond to information, adequate explanation and emotional support from those involved in patient care. This article concentrates on the less common but more severe depressive disorders which require pharmacological strategies in addition to psychosocial interventions. Guidelines are suggested for identifying depressive disorders and the importance of ruling out potentially reversible organic pathology which may be responsible for the mood disturbance is also emphasized. Estimates of the prevalence of depressive disorders among cancer patients are provided and practical advice is offered on the choice of antidepressant, dosage and side-effects.
Get full access to this article
View all access options for this article.